Next Article in Journal
Polypoidal Choroidal Vasculopathy in Asians
Next Article in Special Issue
The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases
Previous Article in Journal
Diagnosis and Management of Hyponatremia in Patients with Aneurysmal Subarachnoid Hemorrhage
Previous Article in Special Issue
Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem Cells
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2015, 4(4), 768-781; doi:10.3390/jcm4040768

Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease

1
Victor Chang Cardiac Research Institute, Lowy Packer Building, 405 Liverpool St., Darlinghurst NSW 2010, Australia
2
St. Vincent's Clinical School and School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington NSW 2052, Australia
3
Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036 Barcelona, Spain
4
Senior Research Fellow, Sydney Medical School, University of Sydney, Sydney NSW 2006, Australia
5
School of Anatomy Physiology & Human Biology and The Harry Perkins Institute for Medical Research (CCTRM), Senior Research Fellow at the University of Western Australia, Crawley WA 6009, Australia
6
International Research Fellow, Victor Chang Cardiac Research Institute, Darlinghurst NSW 2010, Australia
7
Heart Centre for Children, The Children's Hospital at Westmead, Westmead NSW 2145, Australia
8
Sydney Medical School, University of Sydney, Sydney NSW 2006, Australia
9
Ear Science Institute Australia, Centre for Cell Therapy and Regenerative Medicine and School of Surgery, University of Western Australia, Nedlands WA 6009, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Jane Grant-Kels
Received: 22 December 2014 / Revised: 27 March 2015 / Accepted: 10 April 2015 / Published: 22 April 2015
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
View Full-Text   |   Download PDF [162 KB, uploaded 22 April 2015]   |  

Abstract

Congenital heart disease places a significant burden on the individual, family and community despite significant advances in our understanding of aetiology and treatment. Early research in ischaemic heart disease has paved the way for stem cell technology and bioengineering, which promises to improve both structural and functional aspects of disease. Stem cell therapy has demonstrated significant improvements in cardiac function in adults with ischaemic heart disease. This finding, together with promising case studies in the paediatric setting, demonstrates the potential for this treatment in congenital heart disease. Furthermore, induced pluripotent stems cell technology, provides a unique opportunity to address aetiological, as well as therapeutic, aspects of disease. View Full-Text
Keywords: congenital heart disease; hypoplastic left heart; inducible pluripotential stem cells; bioengineered myocardium congenital heart disease; hypoplastic left heart; inducible pluripotential stem cells; bioengineered myocardium
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Bosman, A.; Edel, M.J.; Blue, G.; Dilley, R.J.; Harvey, R.P.; Winlaw, D.S. Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease. J. Clin. Med. 2015, 4, 768-781.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top